BioCryst to Present at Upcoming Investor Conferences
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:
北卡罗来纳州三角研究园，2024年5月7日（GLOBE NEWSWIRE）——BioCryst Pharmicals, Inc.（纳斯达克股票代码：BCRX）今天宣布，该公司将出席以下会议：
- Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET.
- 美国东部时间2024年5月13日星期一下午12点30分在纽约举行的Citizens JMP生命科学会议。
- 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET.
- 2024年加拿大皇家银行资本市场全球医疗保健会议将于美国东部时间2024年5月14日星期二下午3点05分在纽约举行。
- Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET.
- 2024年美国银行医疗保健会议将于美国东部时间2024年5月15日星期三下午5点20分在拉斯维加斯举行。
- H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday, May 20, 2024, at 10:30 a.m. ET.
- H.C. Wainwright 2和 美国东部时间2024年5月20日星期一上午10点30分在纽约举行的年度BioConnect投资者大会。
- Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024, at 9:30 a.m. ET.
- 杰富瑞全球医疗保健会议将于美国东部时间2024年6月6日星期四上午9点30分在纽约举行。
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst's website at
可以在BioCryst网站的 “投资者与媒体” 部分访问网络直播和演示重播的链接，网址为
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn.
关于 BioCryst 制药
BioCryst Pharmicals是一家全球生物技术公司，坚定致力于改善补体介导疾病和其他罕见疾病患者的生活。BioCryst利用其在结构引导药物设计方面的专业知识，开发出针对难以治疗的疾病的同类首创或一流的口服小分子和蛋白质疗法。BioCryst 已将 ORLADEYO 商业化 （berotralstat）是第一种口服、每日一次的血浆激素抑制剂，正在推进小分子和蛋白质疗法的研发管道。欲了解更多信息，请访问或在 LinkedIn 上关注我们。
BCRXW
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
联系我们:
约翰·布鲁斯
+1 919 859 7910
jbluth@biocryst.com
译文内容由第三方软件翻译。